Silence Therapeutics plc Additional Paid in Capital, Common Stock
Silence Therapeutics plc (SLN) had Additional Paid in Capital, Common Stock of $621.15 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-10
- 2026-06-30: Additional Paid in Capital, Common Stock $621.15M.
- 2026-03-31: Additional Paid in Capital, Common Stock $620.01M.
- 2025-12-31: Additional Paid in Capital, Common Stock $617.56M.
- 2025-09-30: Additional Paid in Capital, Common Stock $617.65M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $621.15M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $620.01M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $617.56M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $617.65M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $615.11M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $613.07M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $609.56M 10-K · filed 2026-03-05 |
| 2023-12-31 | $455.76M 10-K · filed 2025-02-27 |